PDE4-IN-29

PDE4-IN-29 (Compound 55) is an orally active and selective inhibitor of PDE4, targeting subtypes such as PDE4A1, PDE4B2, and PDE4D3, with an IC50 value for PDE4D3 of less than 5 nM. It inhibits the degradation of cyclic adenosine monophosphate (cAMP), elevating intracellular cAMP levels and suppressing the release of inflammatory mediators like TNF-α. PDE4-IN-29 holds potential for research in inflammatory diseases such as psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease.